A prospective study on hyperhomocysteinemia as an aggravating factor in chronic venous insufficiency

一项关于高同型半胱氨酸血症作为慢性静脉功能不全加重因素的前瞻性研究

阅读:1

Abstract

The role of hyperhomocysteinemia (HH) in the etiopathogenetics of systemic thrombotic events has been confirmed by numerous studies. However, it has been insufficiently studied as an etiopathogenic factor in chronic venous insufficiency (CVI). The present prospective study included 166 patients with CVI at stages C3-C6. Homocysteine levels and the inflammatory, metabolic and procoagulant profiles of the patients were determined. High-performance liquid chromatography was used to determine the homocysteine level. Within the patients with HH, the thromboembolic risk was analyzed. Smoking was determined to represent the most common procoagulant factor (21.67%), whereas in the subgroup of women, abortions represented a procoagulant factor for 31.93%. The metabolic profile was altered in approximately half of all cases (42.77%), whereas proinflammatory status was a contributing factor in 23.50% of the cases. HH was present in 54.22% of the CVI patients, mainly in the moderate HH category (53.01%), mostly linked to venous ulcers, thrombophlebitis and pulmonary thromboembolisms. The highest average values of homocysteine were recorded in patients >75 years old and when the venous disease age was >20 years (15.03 µmol/l). In summary, in the present study, HH was a contributing factor of CVI alongside the chronic inflammation that is well known in CVI, which increased thrombogenic risk, especially in elderly patients with an advanced age of venous disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。